Cargando…

Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer

Background. Treatment of patients with a biochemical recurrence (BCR) of prostate cancer (PCa) is generally difficult and without valid treatment options. Since 2004 we have been developing therapeutic possibilities for these patients. Methods. We retrospectively analyzed a cohort of 41 patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Osmonov, Daniar K., Aksenov, Alexey V., Boller, Annkathrin, Kalz, Almut, Heimann, Diana, Janssen, Isa, Jünemann, Klaus-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945023/
https://www.ncbi.nlm.nih.gov/pubmed/24688536
http://dx.doi.org/10.1155/2014/321619
_version_ 1782306471762984960
author Osmonov, Daniar K.
Aksenov, Alexey V.
Boller, Annkathrin
Kalz, Almut
Heimann, Diana
Janssen, Isa
Jünemann, Klaus-Peter
author_facet Osmonov, Daniar K.
Aksenov, Alexey V.
Boller, Annkathrin
Kalz, Almut
Heimann, Diana
Janssen, Isa
Jünemann, Klaus-Peter
author_sort Osmonov, Daniar K.
collection PubMed
description Background. Treatment of patients with a biochemical recurrence (BCR) of prostate cancer (PCa) is generally difficult and without valid treatment options. Since 2004 we have been developing therapeutic possibilities for these patients. Methods. We retrospectively analyzed a cohort of 41 patients with a BCR of PCa and a mean followup of 40.3 ± 20.8 months. Group 1 (n = 10): salvage radical prostatectomy (sRP) with SePLND (salvage extended pelvic lymph nodes dissection) (initial treatment: combined brachytherapy). Group 2 (n = 22): SePLND (initial treatment: radical prostatectomy (RP)). Group 3 (n = 9): SePLND (initial treatment: RP and adjuvant radiation therapy (RT)). We observed PSA, PSA-velocity, localization of LNs and LNs+, BCR-free period, and BR (biochemical response). Results. Group 1: 60% with BCR-freedom (mean 27.2 months). Group 2: 63.6% with BCR-freedom (mean 17.5 months). Group 3: 33.3% with BCR-freedom (mean 17.6 months). In total, BCR-freedom was observed in 23 of 41 patients (56.1%) after salvage surgery. 75.6% of all patients showed a BR. 765 LNs were removed and 14.8% of these were LN+. Conclusions. The BCR-free period and BR are comparable in all three groups. Sensibility to ADT can be reestablished and prolonged as a result of SePLND. Multicenter studies are needed for a reliable output.
format Online
Article
Text
id pubmed-3945023
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39450232014-03-31 Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer Osmonov, Daniar K. Aksenov, Alexey V. Boller, Annkathrin Kalz, Almut Heimann, Diana Janssen, Isa Jünemann, Klaus-Peter Adv Urol Research Article Background. Treatment of patients with a biochemical recurrence (BCR) of prostate cancer (PCa) is generally difficult and without valid treatment options. Since 2004 we have been developing therapeutic possibilities for these patients. Methods. We retrospectively analyzed a cohort of 41 patients with a BCR of PCa and a mean followup of 40.3 ± 20.8 months. Group 1 (n = 10): salvage radical prostatectomy (sRP) with SePLND (salvage extended pelvic lymph nodes dissection) (initial treatment: combined brachytherapy). Group 2 (n = 22): SePLND (initial treatment: radical prostatectomy (RP)). Group 3 (n = 9): SePLND (initial treatment: RP and adjuvant radiation therapy (RT)). We observed PSA, PSA-velocity, localization of LNs and LNs+, BCR-free period, and BR (biochemical response). Results. Group 1: 60% with BCR-freedom (mean 27.2 months). Group 2: 63.6% with BCR-freedom (mean 17.5 months). Group 3: 33.3% with BCR-freedom (mean 17.6 months). In total, BCR-freedom was observed in 23 of 41 patients (56.1%) after salvage surgery. 75.6% of all patients showed a BR. 765 LNs were removed and 14.8% of these were LN+. Conclusions. The BCR-free period and BR are comparable in all three groups. Sensibility to ADT can be reestablished and prolonged as a result of SePLND. Multicenter studies are needed for a reliable output. Hindawi Publishing Corporation 2014 2014-02-12 /pmc/articles/PMC3945023/ /pubmed/24688536 http://dx.doi.org/10.1155/2014/321619 Text en Copyright © 2014 Daniar K. Osmonov et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Osmonov, Daniar K.
Aksenov, Alexey V.
Boller, Annkathrin
Kalz, Almut
Heimann, Diana
Janssen, Isa
Jünemann, Klaus-Peter
Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer
title Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer
title_full Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer
title_fullStr Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer
title_full_unstemmed Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer
title_short Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer
title_sort extended salvage pelvic lymph node dissection in patients with recurrent prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945023/
https://www.ncbi.nlm.nih.gov/pubmed/24688536
http://dx.doi.org/10.1155/2014/321619
work_keys_str_mv AT osmonovdaniark extendedsalvagepelviclymphnodedissectioninpatientswithrecurrentprostatecancer
AT aksenovalexeyv extendedsalvagepelviclymphnodedissectioninpatientswithrecurrentprostatecancer
AT bollerannkathrin extendedsalvagepelviclymphnodedissectioninpatientswithrecurrentprostatecancer
AT kalzalmut extendedsalvagepelviclymphnodedissectioninpatientswithrecurrentprostatecancer
AT heimanndiana extendedsalvagepelviclymphnodedissectioninpatientswithrecurrentprostatecancer
AT janssenisa extendedsalvagepelviclymphnodedissectioninpatientswithrecurrentprostatecancer
AT junemannklauspeter extendedsalvagepelviclymphnodedissectioninpatientswithrecurrentprostatecancer